Oxford's coronavirus vaccine AstraZeneca resumes trial after clearance from United Kingdom health regulator
Sep 14 2020
Together with the AstraZeneca vaccine, it is on the list of WHO-monitored list of candidate vaccines on a quest to get approved for industrial production once they complete all three required phases of clinical trials.
The pause came only days after the announcement from the University of Oxford that trials were being expanded, led by AstraZeneca. In a tweet, SII CEO Adar Poonawalla said: "As I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded".
According to a World Health Organization site that tracks vaccine progress, there are now 169 Covid-19 vaccine candidates under development, with 26 in the human trial phase. Moderna is developing this vaccine based on Messenger RNA called mRNA to produce viral proteins in the human body which will help the body to produce antibodies that will prevent one from catching the Covid-19 infection. A woman in the United Kingdom trial was diagnosed with multiple sclerosis in July, but that event, which triggered the first pause, was deemed not to be related to the vaccine. The research team is going to observe the candidates over a period of time.
China National Biotec Group Co., a subsidiary of state-owned Sinopharm, has given two experimental vaccine candidates to hundreds of thousands of people under an emergency-use condition approved by Beijing in July, the company said this week. The vaccine immediately garnered criticism from the worldwide scientific community because of the lack of data on advanced human trials.
According to JSS Hospital sources there have been no reports of adverse events after the vaccine was administered.
ChAdOx1 or the Covishield is a vaccine that is being developed jointly by the University of Oxford, Indian Serum Institute and the British-Swedish Company AstraZeneca.
"Globally some 18,000 individuals have received study vaccines as part of the trial".
When injected into the arm, it instructs muscle cells to make copies of the protein to provoke an immune response.
Somani had issued a show cause notice to SII earlier this week asking it to explain why the permission to conduct trials should not be suspended unless patient safety is established. After this, on September 9, Serum also stopped his trial after DCGI's objection.
Whether it is the first indigenous Covid-19 vaccine- Covaxin, Russia's Sputnik V, Johnson& Johnson's Ad26.Cov2.S, FlueGen's CoroFlu or even Sanofi's vaccine under development, all the above names have a Hyderabad connection. The goal of the large studies is to see if the vaccine is capable of preventing COVID-19, and is safe.
The Russian Institute had launched the clinical trial in June this year and by August, the institute had already begun phase III trials.